文献速递骨质疏松与代谢性骨病

为期12个月抗阻与冲击运动方案或利塞膦酸对绝经后女性髋部骨结构具有相对获益:一项随机对照试验结果

Twelve-month resistance and impact exercise program or risedronate provides a relative benefit to hip bone structure in postmenopausal women: results from a randomized controlled trial.
PubMed 文献 · Osteoporos Int · 2024-02-17

该随机对照试验纳入276名绝经6年内、低骨量的绝经后女性,随机分为运动组(92例)、利塞膦酸组(91例)和对照组(93例),干预12个月。胫骨pQCT各项指标组间变化无显著差异;髋部HSA显示运动与利塞膦酸均对髋部结构有相对获益,但两者之间未发现孰优。

要点

  • 运动组与对照组相比,转子间横截面积、CSMI、截面模量在12个月时差异有统计学意义。
  • 利塞膦酸组与对照组相比,转子间CSMI、截面模量及股骨干多项HSA指标差异有统计学意义。
  • 胫骨pQCT各项指标(体积骨密度、面积、强度估计)组间变化均无显著差异。

核心结论

  • 运动和双膦酸盐可能影响髋部的结构和强度估计,但不影响外周部位(胫骨)。
  • 未发现运动或双膦酸盐在改善髋部骨强度估计方面孰优。

研究设计与样本

  • 随机对照试验,276名绝经6年内的绝经后低骨量女性随机分为运动组92例、利塞膦酸组91例、对照组93例。
  • 运动包括负重慢跑和渐进抗阻训练;利塞膦酸为每月150 mg;所有组均补充钙和维生素D。
  • 基线与第6、12个月行pQCT和DXA检查,组间随时间比较。
  • 参与者平均(±SD)年龄54.5(±3.2)岁,绝经后平均36.7(±40.7)个月。

主要发现

  • pQCT各项指标(体积骨密度、面积和强度估计)的变化组间无显著差异。
  • 12个月时运动组与对照组HSA平均百分比差异(95%CI):转子间横截面积2.25%(0.28, 4.12)(p = .03)、CSMI 5.67%(1.47, 9.87)(p < .01)、截面模量4.38%(1.02, 7.74)(p = .01);窄颈平均皮质厚度2.37%(-0.08, 4.83)(p = .031)。
  • 利塞膦酸组与对照组HSA平均百分比差异(95%CI):转子间CSMI 4.28%(-0.24, 8.81)(p = .03)、截面模量3.35%(-0.21, 6.91)(p = .03);股骨干骨膜下宽度0.82%(0.05, 1.58)(p = .047)、CSMI 2.53%(0.88, 4.18)(p = .004)、截面模量1.57%(0.34, 2.8)(p = .008)。
  • 与对照组1.27%(0.13, 2.41)(p = .04)和利塞膦酸组1.31%(0.23, 2.39)(p = .03)相比,运动维持了股骨颈干角。
  • 运动组与利塞膦酸组之间HSA结局随时间变化的其他差异均无统计学意义。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Bone strength estimates are important for fracture prevention. This study compared bone strength changes in postmenopausal women with low bone mass who were assigned to 12 months of exercise, a bone medication, or control. Exercise and bone medications benefited structure at the hip. Structure should be considered in fracture prevention research. PURPOSE: Exercise and bisphosphonates reduce fracture risk, but their impact on estimates of bone strength remains uncertain. This study compared changes in tibial bone strength using peripheral quantitative computed tomography (pQCT) and hip structure analysis (HSA) outcomes from dual-energy X-ray absorptiometry (DXA) scans in postmenopausal women with low bone mass assigned to 12 months of exercise, risedronate, or control. METHODS: In this RCT, 276 postmenopausal women within 6 years of menopause were randomly assigned to three groups: exercise (92), risedronate (91), or control (93). Exercise included weighted jogging and progressive resistance exercises; risedronate treatment was 150 mg monthly; all groups received calcium and vitamin D. pQCT and DXA images were obtained at baseline and 6 and 12 months and compared between groups over time. RESULTS: Participants had a mean (± SD) age of 54.5 (± 3.2) years with an average of 36.7 (± 40.7) months postmenopause. No significant differences were found between groups for the change in pQCT outcomes (volumetric bone mineral density, area, and strength estimates). At 12 months, mean percent differences (95% CI) in HSA measures between exercise and controls were as follows: intertrochanteric, cross-sectional area 2.25% (0.28, 4.12) (p = .03), cross-sectional moment of inertia (CSMI) 5.67% (1.47, 9.87) (p < .01), and section modulus (SM) 4.38% (1.02, 7.74) (p = .01), and narrow neck, average cortical thickness 2.37% (-0.08, 4.83) (p = .031). Mean percent differences (95% CI) in HSA measures between risedronate and control were as follows: intertrochanteric, CSMI 4.28% (-0.24, 8.81) (p = .03) and SM 3.35% (-0.21, 6.91) (p = .03), and shaft, subperiosteal width 0.82% (0.05, 1.58) (p = .047), CSMI 2.53% (0.88, 4.18) (p = .004), and SM 1.57% (0.34, 2.8) (p = .008). Exercise maintained neck-shaft angle compared to both control 1.27% (0.13, 2.41) (p = .04) and risedronate 1.31% (0.23, 2.39) (p = .03). All other differences for changes in HSA outcomes over time were not significantly different between the exercise and risedronate groups. CONCLUSION: Exercise and bisphosphonates may influence structural and strength estimates at the hip, but not at peripheral sites (tibia). Neither exercise nor bisphosphonates were found to be superior in improving estimates of hip bone strength.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Blay R, Flores LE, Kupzyk K, et al. Twelve-month resistance and impact exercise program or risedronate provides a relative benefit to hip bone structure in postmenopausal women: results from a randomized controlled trial. Osteoporos Int. 2024. PMID: 38368307. doi:10.1007/s00198-023-07008-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。